BioHarvest Sciences (NASDAQ:BHST) Announces Earnings Results, Beats Estimates By $0.01 EPS

Posted by Don Miller on Apr 1st, 2026

BioHarvest Sciences (NASDAQ:BHST – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01, Zacks reports. The business had revenue of $9.07 million during the quarter, compared to the consensus estimate of $9.24 million. BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%.

Here are the key takeaways from BioHarvest Sciences’ conference call:

Q4 revenue was $9.1M (+25% YoY) and full‑year revenue was $34.5M (+37% YoY), with Q4 adjusted EBITDA of $0.5M, improved gross margins (~59%), and year‑end cash of $23M, reflecting materially stronger profitability and liquidity.
The VINIA direct‑to‑consumer business exceeded 85,000 active users, earned the #1 U.S. resveratrol brand position, and the new VINIA Blood Flow Hydration launch is showing strong early traction (15% of new‑customer revenue and ~4.8–4.9 ratings), prompting a shift to digital marketing to reach younger cohorts.
The CDMO unit hit a major technical milestone by completing stage one for a rare fragrance plant (first‑ever stable cell culture), retains 20% ownership of resulting compositions, has four active third‑party programs (including Tate & Lyle and Saffron Tech), and expects external CDMO revenue to rise toward $4–6M in 2026.
Management is investing heavily in CDMO and manufacturing capabilities (AI, process engineering, elicitation center) and increasing marketing spend, which will make near‑term results lumpy and raise operating expenses but is presented as a deliberate trade‑off to accelerate growth in 2027–2028.

BioHarvest Sciences Stock Performance

BHST traded up $0.00 during trading on Wednesday, reaching $4.34. 5,384 shares of the company’s stock were exchanged, compared to its average volume of 26,156. The company has a market capitalization of $85.17 million, a P/E ratio of -6.39 and a beta of 1.14. The company has a quick ratio of 1.02, a current ratio of 1.35 and a debt-to-equity ratio of 0.30. The business has a 50 day moving average price of $4.61 and a 200 day moving average price of $6.65. BioHarvest Sciences has a fifty-two week low of $4.10 and a fifty-two week high of $12.80.

Institutional Trading of BioHarvest Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC acquired a new stake in BioHarvest Sciences during the 4th quarter worth approximately $61,000. HRT Financial LP acquired a new stake in shares of BioHarvest Sciences in the 4th quarter valued at about $75,000. Jane Street Group LLC acquired a new position in shares of BioHarvest Sciences during the fourth quarter worth about $145,000. Alyeska Investment Group L.P. bought a new position in shares of BioHarvest Sciences during the fourth quarter worth about $3,929,000. Finally, Marshall Wace LLP acquired a new stake in BioHarvest Sciences in the 4th quarter valued at approximately $110,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on BHST. Roth Mkm initiated coverage on shares of BioHarvest Sciences in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Friday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $13.00.

View Our Latest Stock Analysis on BHST

BioHarvest Sciences Company Profile

(Get Free Report)

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.